User:Mr. Ibrahem/Atezolizumab

Atezolizumab, sold under the brand name Tecentriq, is a medication used to treat urothelial carcinoma, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), hepatocellular carcinoma (HCC), triple-negative breast cancer, and melanoma. Use is often only when specific mutations are present. It is given by gradual injection into a vein.

Common side effects include tiredness, reduced appetite, nausea, cough, difficulty breathing, diarrhea, rash, fever, muscle pain, weakness, itching, and urinary tract infection. Other side effects may include immune-mediated disorders including pneumonitis, colitis, and hepatitis. Use in pregnancy may harm the baby. It is a monoclonal antibody that attaches to and blocks programmed cell death-ligand 1 (PD-L1). This allows the immune system to attack cancer cells.

Atezolizumab was approved for medical use in the United States in 2016 and Europe in 2017. In the United Kingdom 1.2 grams costs the NHS about £3,800 as of 2021. This amount in the United States costs about 10,300 USD.